GH insider filing: 1,402 RSUs vested; 594 shares sold at $54.79

Q: What transactions did Chris Freeman report on the Form 4 for Guardant Health (GH)?

The Form 4 reports the vesting of 1,402 RSUs treated as an acquisition at $0, company retention of those shares for tax withholding, and a disposition of 594 shares at $54.79 on 09/15/2025 .

Q: How many Guardant Health (GH) shares does Chris Freeman beneficially own after the reported transactions?

After the reported transactions, Freeman beneficially owns 49,629 shares .

Q: What grant do the vested RSUs relate to?

The vested RSUs relate to an award granted on June 9, 2023 , which vests over a three-year period with an initial 33% vesting on June 15, 2024 and the remainder vesting in equal quarterly installments thereafter.

Q: Who signed the Form 4 filing for Chris Freeman?

The Form 4 was signed on behalf of Chris Freeman by John G. Saia, as attorney-in-fact , on 09/17/2025 .

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Chris Freeman, Chief Commercial Officer of Guardant Health (GH), reported insider transactions dated 09/15/2025. The filing shows 1,402 restricted stock units vested and were treated as an acquisition at $0, increasing his beneficial ownership to 50,223 shares before subsequent disposition. The company retained 1,402 shares to satisfy tax withholding related to the vesting. Separately, Freeman disposed of 594 shares at $54.79, leaving him with 49,629 shares beneficially owned after the reported transactions.

Positive

Insider retains significant ownership: Freeman continues to beneficially own 49,629 shares after the transactions.
Standard compensation mechanics: Vesting of 1,402 RSUs and company withholding for taxes were disclosed transparently.

Negative

Minor disposition: Freeman disposed of 594 shares at $54.79, reducing his holdings from 50,223 to 49,629 shares.

Insights

TL;DR: Routine insider vesting with a small open-market sale; no material change to ownership stake.

The Form 4 reflects a customary vesting of 1,402 RSUs and a contemporaneous withholding of shares to cover taxes, plus a reported disposition of 594 shares at $54.79. The net holding moved from 50,223 to 49,629 shares, a modest change relative to company-wide float. These actions are typical compensation and tax procedures for executives and are not presented as part of a planned exit or major reallocation.

TL;DR: Disclosure follows standard Section 16 reporting for vested RSUs and an associated sale for tax obligations.

The filing documents the vesting schedule tied to a 2023 RSU grant and explains tax-withholding share retention by the company. The separate reported sale of 594 shares at $54.79 is disclosed and signed by an attorney-in-fact, meeting procedural requirements. No governance red flags or deviations from standard insider reporting practices are evident from the disclosed items.

Insider Trade Summary

1,402 shares exercised/converted

Mixed 3 txns

Insider Freeman Chris

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	1,402	$0.00	--
Exercise	Common Stock	1,402	$0.00	--
Tax Withholding	Common Stock	594	$54.79	$33K

Holdings After Transaction: Restricted Stock Units — 4,206 shares (Direct); Common Stock — 50,223 shares (Direct)

Footnotes (1)

These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. This represents a restricted stock unit award granted on June 9, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on June 15, 2024. The remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. Not applicable for Restricted Stock Units.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

09/17/2025 - 05:15 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Freeman Chris

(Last)

(First)

(Middle)

3100 HANOVER STREET

(Street)

PALO ALTO

94304

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	09/15/2025		M		1,402	A	$0	50,223	D
Common Stock	09/15/2025		F		594⁽¹⁾	D	$54.79	49,629	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	$0	09/15/2025		M			1,402	⁽²⁾	⁽³⁾	Common Stock	1,402	$0	4,206	D

Explanation of Responses:

1. These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.

2. This represents a restricted stock unit award granted on June 9, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on June 15, 2024. The remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.

3. Not applicable for Restricted Stock Units.

Remarks:

	/s/ John G. Saia, as attorney-in-fact for Chris Freeman	09/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What transactions did Chris Freeman report on the Form 4 for Guardant Health (GH)?

The Form 4 reports the vesting of 1,402 RSUs treated as an acquisition at $0, company retention of those shares for tax withholding, and a disposition of 594 shares at $54.79 on 09/15/2025.

How many Guardant Health (GH) shares does Chris Freeman beneficially own after the reported transactions?

After the reported transactions, Freeman beneficially owns 49,629 shares.

Why were some shares retained by the company in this Form 4 filing?

The company retained shares to satisfy the reporting person's tax withholding obligations related to the vesting of the restricted stock units, and the amount retained was not in excess of the tax liability.

What grant do the vested RSUs relate to?

The vested RSUs relate to an award granted on June 9, 2023, which vests over a three-year period with an initial 33% vesting on June 15, 2024 and the remainder vesting in equal quarterly installments thereafter.

Who signed the Form 4 filing for Chris Freeman?

The Form 4 was signed on behalf of Chris Freeman by John G. Saia, as attorney-in-fact, on 09/17/2025.